Sugi Predict

Sugi Predict / Targets / GOLGA2

GOLGA2

Golgin subfamily A member 2 · Q08379 · GOLGA2 on Sugi Atlas →

0 patent compounds predicted against GOLGA2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to GOLGA2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease PHASE4COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
Ambroxol as a Treatment for Parkinson's Disease Dementia PHASE2UNKNOWN
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47) PHASE1/PHASE2NOT_YET_RECRUITING
Janus Kinase Inhibition in Granuloma Annulare PHASE2ACTIVE_NOT_RECRUITING
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy PHASE2COMPLETED
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II) PHASE2SUSPENDED
Registry Gangliosidoses nanUNKNOWN
Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD) nanCOMPLETED
Biomarker Analysis for GBA Associated Parkinson's Disease nanUNKNOWN
A Multicenter Phenotype-Genotype Analysis of LGMD Patients in China nanENROLLING_BY_INVITATION
Genetic Investigations in Children With Developmental and Epileptic Encephalopathies in Ho Chi Minh City, Vietnam nanUNKNOWN
GNAO1 Natural History Study nanUNKNOWN
Non Motor Symptoms in Glucocerebrosidase-related Parkinson's Disease nanENROLLING_BY_INVITATION
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders nanRECRUITING
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy nanUNKNOWN
Genetic Studies of Lysosomal Storage Disorders nanENROLLING_BY_INVITATION
A Natural History of Late Onset Tay-Sachs Disease nanCOMPLETED
Clinical Trial Readiness for the Dystroglycanopathies nanRECRUITING
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease nanCOMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease nanCOMPLETED
Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations nanCOMPLETED
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease nanRECRUITING
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study nanRECRUITING
Genetic Analysis of Gray Platelet Syndrome nanCOMPLETED
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation nanUNKNOWN
Positional Cloning of the Gene(s) Responsible for Alagille Syndrome nanCOMPLETED
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a GOLGA2 binder may also engage these)

ProteinNameSimilarity
Q921M4 — 1.000 Q921M4 →
Q62839 — 1.000 Q62839 →
Q5RCR6 — 0.994 Q5RCR6 →
A4FUG8 — 0.993 A4FUG8 →
A7YH32 — 0.993 A7YH32 →
Q9H5N1 — 0.993 Q9H5N1 →
Q9WUJ3 — 0.992 Q9WUJ3 →
B3EX63 — 0.991 B3EX63 →
Q9WTX8 — 0.991 Q9WTX8 →
Q96ST8 — 0.991 Q96ST8 →
Q5VU43 — 0.991 Q5VU43 →
D3YV10 — 0.991 D3YV10 →
Q80YT7 — 0.990 Q80YT7 →
Q61043 — 0.990 Q61043 →
Q5U3A8 — 0.990 Q5U3A8 →
Q8IYE1 — 0.990 Q8IYE1 →
Q15025 — 0.990 Q15025 →
Q8BIJ7 — 0.990 Q8BIJ7 →
A1IH00 — 0.989 A1IH00 →
Q8HZ57 — 0.989 Q8HZ57 →
Q8TD31 — 0.989 Q8TD31 →
Q62036 — 0.989 Q62036 →
Q5SPX1 — 0.989 Q5SPX1 →
Q8N4C6 — 0.989 Q8N4C6 →
Q6P9Q6 — 0.989 Q6P9Q6 →
G9G127 — 0.989 G9G127 →
Q9WUU8 — 0.989 Q9WUU8 →
Q8K2I2 — 0.989 Q8K2I2 →
Q80YF0 — 0.989 Q80YF0 →
Q62835 — 0.988 Q62835 →